Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases

Clinical and Experimental Immunology

Volumn 176, Issue 1, 2014, Pages 1-10

  Patterson, H ^a   Nibbs, R ^a   Mcinnes, I ^a   Siebert, S ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Autoimmunity; Novel biological therapies; Protein kinases; Signalling signal transduction

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 5 (2 AMINO 4 PYRIMIDINYL) 4 (4 FLUOROPHENYL) 1 (4 PIPERIDINYL)IMIDAZOLE; AC 430; ADELATINIB; AMG 548; ANTIINFLAMMATORY AGENT; BARICITINIB; BAY 613606; CEP 33779; DORAMAPIMOD; ER 27319; FOSTAMATINIB; GLPG 0634; JANUS KINASE; JANUS KINASE INHIBITOR; LESTAURTINIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PROTEIN KINASE SYK; PROTEIN KINASE SYK INHIBITOR; R 112; R 343; R 348; RUXOLITINIB; SCIO 323; SEMAPIMOD; TOFACITINIB; UNCLASSIFIED DRUG; VX 702;

ALLERGIC ASTHMA; ALLERGIC DISEASE; ALLERGIC RHINITIS; ARTHRITIS; AUTOIMMUNE DISEASE; CELL GROWTH; CELL PROLIFERATION; CROHN DISEASE; DRUG APPROVAL; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY DISEASE; KERATOCONJUNCTIVITIS SICCA; LIVER TOXICITY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SKIN TOXICITY; SYSTEMIC LUPUS ERYTHEMATOSUS; ULCERATIVE COLITIS;

AUTOIMMUNITY; NOVEL BIOLOGICAL THERAPIES; PROTEIN KINASES; SIGNALLING/SIGNAL TRANSDUCTION;

ANTI-INFLAMMATORY AGENTS; AUTOIMMUNE DISEASES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; JANUS KINASES; MODELS, BIOLOGICAL; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 84895514264     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12248     Document Type: Review

References (107)

1. Asadullah K, Volk H, Sterry W. Novel immunotherapies for psoriasis. Trends Immunol 2002; 23:47-53.
2. Balagué C, Kunkel SL, Godessart N. Understanding autoimmune disease: new targets for drug discovery. Drug Discov Today 2009; 14:926-934.
3. Steinman L, Merrill JT, McInnes IB, Peakman M. Optimization of current and future therapy. Nat Med 2012; 18:59-65.
4. Gaestel M, Mengel A, Bothe U, Asadullah K. Protein kinases as small molecule inhibitor targets in inflammation. Curr Med Chem 2007; 14:2214-2234.
5. Grant SK. Therapeutic protein kinase inhibitors. Cell Mol Life Sci 2009; 66:1163-1177.
6. Kontzias A, Laurence A, Gadina M, O'Shea JJ. Kinase inhibitors in the treatment of immune-mediated disease. F1000 Med Rep 2012; 4:5.
7. Manning G, Plowman GD, Hunter T, Sudarsanam S. Evolution of protein kinase signaling from yeast to man. Trends Biochem Sci 2002; 27:514-520.
8. Ubersax JA, Ferrell JE Jr. Mechanisms of specificity in protein phosphorylation. Nat Rev Mol Cell Biol 2007; 8:530-541.
9. Asadullah K, Gaestel M. Protein kinase inhibitors for the treatment of inflammation - an overview. Antiinflamm Antiallergy Agents Med Chem 2007; 6:3-4.
10. Cohen P. Protein kinases - the major drug targets of the twenty-first century? Nat Rev Drug Discov 2002; 1:309-315.
11. Dar AC, Shoka KM. The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling. Annu Rev Biochem 2011; 80:769-795.
12. Shen K, Hines AC, Schwarzer D, Pickin KA, Cole PA. Protein kinase structure and function analysis with chemical tools. Biochim Biophys Acta 2005; 1754:65-78.
13. Klumpp S, Krieglstein J. Reversible phosphorylation of histidine residues in proteins from vertebrates. Sci Signal 2009; 2:pe13.
14. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002; 298:1912-1934.
15. Burnett G, Kennedy EP. The enzymic phosphorylation of proteins. J Biol Chem 1954; 211:969-980.
16. Cohen P. The origins of protein phosphorylation. Nat Cell Biol 2002; 4:E127-130.
17. Edelman AM, Blumenthal DK, Krebs EG. Protein serine/threonine kinases. Annu Rev Biochem 1987; 56:567-613.
18. Fischer EH, Krebs EG. Relationship of structure to function of muscle phosphorylase. Fed Proc 1966; 25:1511-1520.
19. Krebs EG. The enzymology of control by phosphorylation. In: Boyer PD, Krebs EG, eds. The enzymes: control by phosphorylation Part A: general features: specific enzymes, vol. 17. New York: Academic Press, 1986:3-20.
20. Melnikova I, Golden J. Targeting protein kinases. Nat Rev Drug Discov 2004; 3:993-994.
21. Vlahovic G, Crawford J. Activation of tyrosine kinases in cancer. Oncologist 2003; 8:531-538.
22. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009; 9:28-39.
23. Lindstrom TM, Robinson WH. A multitude of kinases - which are the best targets in treating rheumatoid arthritis? Rheum Dis Clin North Am 2010; 36:367-383.
24. Kontzias A, Kotlyar A, Laurence A, Changelian P, O'Shea JJ. Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. Curr Opin Pharmacol 2012; 12:464-470.
25. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signalling proteins. Science 1994; 264:1415-1421.
26. Seavey MM, Dobrzanksi P. The many faces of Janus kinase. Biochem Pharmacol 2012; 83:1136-1145.
27. Leonard WJ. Role of Jak kinases and STATs in cytokine signal transduction. Int J Hematol 2001; 73:271-277.
28. Ghoreschi K, Jesson MI, Li X etal. Modulation of innate and adaptive immune responses by tofacitinib (CP-690, 550). J Immunol 2011; 186:4234-4243.
29. Pesu M, Candotti F, Husa M, Hofmann SR, Notarangelo LD, O'Shea JJ. Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs. Immunol Rev 2005; 203:127-142.
30. Yamaoka K, Saharinen P, Pesu M, Holt VE III, Silvennoinen O, O'Shea JJ. The Janus kinases (Jaks). Genome Biol 2004; 5:253.
31. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells responds to interferons. Annu Rev Biochem 1998; 67:227-264.
32. Leonard WJ, O'Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol 1998; 16:293-322.
33. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signalling. Immunol Rev 2009; 228:273-287.
34. Rane SG, Reddy EP. JAK3: a novel JAK kinase associated with terminal differentiation of hematopoetic cells. Oncogene 1994; 9:2415-2423.
35. Kawamura M, McVicar DW, Johnston JA etal. Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes. Proc Natl Acad Sci USA 1994; 91:6374-6378.
36. Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007; 7:673-683.
37. Macchi P, Villa A, Giliani S etal. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 1995; 377:65-68.
38. Pesu M, Laurence A, Kishore N, Zwillich SH, Chan G, O'Shea JJ. Therapeutic targeting of Janus kinases. Immunol Rev 2008; 223:132-142.
39. Walker JG, Ahem MJ, Coleman M. Expression of Jak3, STAT1, STAT4 and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis. Ann Rheum Dis 2006; 65:149-156.
40. Changelian PS, Flanagan ME, Ball DJ etal. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003; 302:875-878.
41. Kudlacz E, Perry B, Sawyer P etal. The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. Am J Transplant 2004; 4:51-57.
42. Milici AJ, Kudlacz EM, Audoly L, Zwillich S, Changelian P. Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Res Ther 2008; 10:R14.
43. Paniagua R, Si MS, Flores MG etal. Effects of JAK3 inhibition with CP-690, 550 on immune cell populations and their functions in nonhuman primate recipients of kidney allografts. Transplantation 2005; 80:1283-1292.
44. Fleischmann R, Kremer J, Cush J etal. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012; 367:495-507.
45. Burmester GR, Blanco R, Charles-Schoeman C etal. Tofacitinib (CP-690, 550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 2013; 381:451-460.
46. Sandborn WJ, Ghosh S, Panes J etal. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012; 367:616-624.
47. Strober B, Buonanno M, Clark JD etal. Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment. Br J Dermatol 2013; 169:992-999.
48. European Medicines Agency. Pending EC decisions: Xeljanz. 2013. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002542/smops/Negative/human_smop_000501.jsp&mid=WC0b01ac058008d7aa (accessed 1 October 2013).
49. Boy MG, Wang C, Wilkinson BE etal. Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690, 550 in patients with psoriasis. J Invest Dermatol 2009; 129:2299-2302.
50. Kremner JM, Bloom BJ, Breedveld FC etal. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690, 550 versus placebo. Arthritis Rheum 2009; 60:1895-1905.
51. Damsker JM, Hansen AM, Caspi RR. Th1 and Th17 cells: adversaries and collaborators. Ann NY Acad Sci 2010; 1183:211-221.
52. Ghoreschi K, Thomas P, Breit S etal. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med 2003; 9:40-46.
53. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007; 7:429-442.
54. Wilson NJ, Boniface K, Chan JR etal. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007; 8:950-957.
55. National Institute of Health - Clinical Trials.gov. Tofacitinib search results. 2013. Available at: http://clinicaltrials.gov/ct2/results?term=tofacitinib&Search=Search (accessed 1 October 2013).
56. Williams W, Scherle P, Shi J etal. A randomized placebo-controlled study of INCB018424, a selective Janus kinase 1 & 2 (JAK1&2) inhibitor in rheumatoid arthritis. Arthritis Rheum 2008; 58:S431.
57. Mesa RA. Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis. IDrugs 2010; 13:394-403.
58. Spencer-Green G, Fan F, Frankovic B, Luo X, Hoock T, Damjanov N. Dose ranging study of VX-509, an oral selective Jak3 inhibitor, as monotherapy in patients with active rheumatoid arthritis (RA). Arthritis Rheum 2011; 63:L3.
59. Dong C, Davis RJ, Flavell RA. MAP kinases in the immune response. Annu Rev Immunol 2002; 20:55-72.
60. Widmann C, Gibson S, Jarpe MB, Johnson GL. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev 1999; 79:143-180.
61. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001; 81:807-869.
62. Schaeffer HJ, Weber MJ. Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol 1999; 19:2435-2444.
63. Wada T, Penninger JM. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 2004; 23:2838-2849.
64. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001; 410:37-40.
65. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000; 103:239-252.
66. Coulombe P, Meloche S. Atypical mitogen-activated protein kinases: structure, regulation and functions. Biochim Biophys Acta 2007; 1773:1376-1387.
67. Sweeney SE, Firestein GS. Mitogen activated protein kinase inhibitors: where are we now and where are we going? Ann Rheum Dis 2006; 65:83-88.
68. Manning AM, Davis RJ. Targeting JNK for therapeutic benefit: from junk to gold? Nat Rev Drug Discov 2003; 2:554-565.
69. Han Z, Boyle DL, Aupperle KR, Bennet B, Manning AM, Firestein GS. Jun N-terminal kinase in rheumatoid arthritis. J Pharmacol Exp Ther 1999; 291:124-130.
70. Schett G, Tohidast-Akrad M, Smolen JS etal. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 2000; 43:2501-2512.
71. Badger AM, Bradbeer JN, Votta B, Lee JC, Adams JL, Griswold DE. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther 1996; 279:1453-1461.
72. Jackson JR, Bolognese B, Hillegass L etal. Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models. J Pharmacol Exp Ther 1998; 284:687-692.
73. Brinkman BM, Telliez JB, Schievella AR, Lin LL, Goldfield AE. Engagement of tumour necrosis factor (TNF) receptor 1 leads to ATF-2 and p38 mitogen-activated protein kinase-dependent TNF-alpha gene expression. J Biol Chem 1999; 274:30882-30886.
74. Krautwald S. IL-16 activates the SAPK signalling pathway in CD4+ macrophages. J Immunol 1998; 160:5874-5879.
75. Tibbles LA, Woodgett JR. The stress-activated protein kinase pathways. Cell Mol Life Sci 1999; 55:1230-1254.
76. Hollenbach E, Neumann M, Vieth M, Roessner A, Malfertheiner P, Naumann M. Inhibition of p39 MAP kinase - and RICK/NF-kappaB-signalling suppresses inflammatory bowel disease. FASEB J 2004; 18:1550-1552.
77. Hommes D, van den Blink B, Plasse T etal. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 2002; 122:7-14.
78. Lee MR, Dominguez C. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38 protein. Curr Med Chem 2005; 12:2979-2994.
79. Dotan I, Rachmilewitz D, Schreiber S etal. A randomised placebo-controlled multicentre trial of intravenous semapimod HCI for moderate to severe Crohn's disease. Gut 2010; 59:760-766.
80. Cohen SB, Cheng TT, Chindalore V etal. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum 2009; 60:335-344.
81. Damjanov N, Kauffman RS, Spencer-Green GT. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum 2009; 60:1232-1241.
82. Genovese MC, Cohen SB, Wofsy D etal. A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis. J Rheumatol 2011; 38:846-854.
83. Mocsai A, Ruland J, Tybulewicz VLJ. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol 2010; 10:387-402.
84. Cambier JC. New nomenclature for the Reth motif (or ARH1/TAM/ARAM/YXXL). Immunol Today 1995; 16:110.
85. Reth M. Antigen receptor tail clue. Nature 1989; 338:383-384.
86. Kurosaki T, Takata M, Yamanashi Y etal. Syk activation by the Src-family tyrosine kinase in the B cell receptor signaling. J Exp Med 1994; 179:1725-1729.
87. Taniguchi T, Kobayashi T, Kondo J etal. Molecular cloning of a porcine gene syk that encodes a 72-kDa protein-tyrosine kinase showing high susceptibility to proteolysis. J Biol Chem 1991; 266:15790-15796.
88. Kurosaki T. Regulation of B cell fates by BCR signaling components. Curr Opin Immunol 2002; 14:341-347.
89. Sada K, Takano T, Yanagi S, Yamamura H. Structure and function of Syk protein-tyrosine kinase. J Biochem 2001; 130:177-186.
90. Turner M, Schweighoffer E, Colucci F, Di Santo JP, Tybulewicz VL. Tyrosine kinase SYK: essential functions for immunoreceptor signalling. Immunol Today 2000; 21:148-154.
91. Robak T, Robak E. Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders. Expert Opin Invest Drugs 2012; 21:921-947.
92. Chaudhary A, Fresquez TM, Naranjo MJ. Tyrosine kinase Syk associates with Toll-like receptor 4 and regulates signaling in human monocytic cells. Immunol Cell Biol 2007; 85:249-256.
93. Mocsai A, Zhou M, Meng F, Tybulewicz VL, Lowell CA. Syk is required for integrin signalling in neutrophils. Immunity 2002; 16:547-558.
94. Takada Y, Aggarwal BB. TNF activates Syk protein tyrosine kinase leading to TNF-induced MAPK activation, NF-kappaB activation, and apoptosis. J Immunol 2004; 173:1066-1077.
95. Watson SP, Auger JM, McCarty OJ, Pearce AC. GPVI and integrin alphaIIb beta3 signaling in platelets. J Thromb Haemost 2005; 3:1752-1762.
96. Willeke T, Schymeinsky J, Prange P, Zahler S, Walzog B. A role for Syk-kinase in the control of the binding cycle of the beta2 integrins (CD11/CD18) in human polymorphonuclear neutrophils. J Leukoc Biol 2003; 74:260-269.
97. Bhagwat SS. Kinase inhibitors for the treatment of inflammatory and autoimmune disorders. Purinergic Signal 2009; 5:107-115.
98. Wong BR, Grossbard EB, Payan DG, Masuda ES. Targeting Syk as a treatment for allergic and autoimmune disorders. Expert Opin Investig Drugs 2004; 13:743-762.
99. Braselmann S, Taylor V, Zhao H etal. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signalling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther 2006; 319:998-1008.
100. Cha HS, Boyle DL, Inoue T etal. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J Pharmacol Exp Ther 2006; 317:571-578.
101. Pine PR, Chang B, Schoettler N etal. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin Immunol 2007; 124:244-257.
102. Weinblatt ME, Kavanaugh A, Burgos-Vargas R etal. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 2008; 58:3309-3318.
103. Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 2010; 363:1303-1312.
104. Genovese MC, Kavanaugh A, Weiblatt ME etal. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum 2011; 63:337-345.
105. Boers M. Syk kinase inhibitors for rheumatoid arthritis: trials and tribulations. Arthritis Rheum 2011; 63:329-330.
106. National Institute of Health - Clinical Trials.gov. NCT01591044. 2013. Available at: http://clinicaltrials.gov/ct2/results?term=R343&Search=Search (accessed 1 October 2013).
107. Norman P. A novel Syk kinase inhibitor suitable for inhalation: R-343(?)-WO-2009031011. Expert Opin Ther Pat 2009; 19:1469-1472.